Clinical Trial

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 14, 2023 (before its estimated August 4, 2026 completion). Its status may not reflect the trial's current state.
Summary
Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer. Therefore, more effective treatments are urgently needed. This study is designed to evaluate the efficacy and safety of the Surufatinib for Locally Advanced Thyroid Cancer.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05989425
Lead Sponsor Fudan University
Conditions Differentiated Thyroid Cancer
Enrollment 32 participants
Start Date 2023-08-04
Primary Completion 2026-08-04 (estimated)
Study Completion 2026-08-04 (estimated)
Updated on ClinicalTrials.gov 2023-08-14